Abbott and Daiichi Sankyo acclaimed in great places to work survey
pharmafile | May 31, 2010 | News story | Business Services | Abbott, Daiichi Sankyo
The Great Place to Work Institute has named Abbott as one of the Top 50 Best Workplaces in the UK, the second consecutive year in a row the pharma company has been included on the list.
The Great Place to Work Institute evaluates the degree of trust at organisations by analysing employee responses to its Trust Index Employee Survey. The research also encompasses key metrics that determine a leading working environment, from the benefits available to employees through to levels of employee engagement with senior management.
Abbott’s HR Director, Amanda White says: “This award is important recognition of Abbott’s continued success in the UK as both a business and an employer. Abbott is a great place to work to make a difference to the lives of others, connecting employees with their potential through extensive development programmes and a multitude of career paths.”
Abbott says it has a long track record of providing a great place to work for its employees. Initiatives such as Abbott Life offer a modern and flexible range of benefits (such as holiday buy/sell, childcare vouchers and learning account) that employees can match to their personal circumstances. In addition, Abbott runs programmes such as Targeting Success, which takes high-potential employees through a year-long development programme that includes a volunteering project in their local community.
Employees’ anonymous feedback from the Great Place to Work survey further demonstrates Abbott’s level of employee engagement.
White says: “Abbott genuinely cares about us as people as well as employees. The opportunity to participate in community projects is fantastic as you help the local community plus get some great team building often with people you wouldn’t usually work with.
“The opportunity for further development is always there and encouraged. That opportunity is open to all who wish to find it, and if further development is not within one’s expectations then it is OK to stay where you are doing the job that you enjoy.”
Abbott employs approximately 83,000 people and markets its products in more than 130 countries. It has been operating in the UK for more than 70 years and currently has operations in Maidenhead, Berkshire (UK Headquarters), Hampshire, Kent, Lancashire, the Midlands and Oxfordshire. An ‘Investor in People’ and accredited Best Company, Abbott employs approximately 2,000 people nationwide. Abbott has received a number of industry awards recently, including being named the world’s most admired company in its industry sector in 2010 by US magazine Fortune.
Daiichi Sankyo
The UK operations of Japanese pharmaceutical companies were also ranked in the survey.
Dr Simon Clough, managing director of Daiichi Sankyo UK commented: “The performance-driven culture at Daiichi Sankyo has been integral to the success of our business for many years. We set high standards, work hard, have fun and treat people as individuals. This culture is delivered with a high degree of accountability and transparency which is measured across the company.”
Based in Gerrards Cross, Buckinghamshire, the company has around 130 employees across a number of divisions. These consist of Primary & Secondary Care Business Units, Medical and Regulatory, Business Intelligence, Finance, IT, People Services and Performance Development teams. The company says it is able to attract the best people by investing in technology, business intelligence and competitive employment benefits.
The Great Place to Work Institute
The UK’s Best Workplaces Programme is run by the Great Place to Work Institute UK, which forms part of the world’s largest programme to recognise excellence in people management.
Related Content
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), …
